Astaxanthin
Extended male mice lifespan significantly in ITP ( ref ). Alleviated NASH in humans. (a) Representative H&E-stained liver sections from two subjects with NASH before and after treatment revealed that astaxanthin improved steatohepatitis after 24 weeks of treatment. (b) NAFLD activity score (NAS) in NASH subjects dropped on astaxanthin (AX, n = 7). P < 0.05 vs. pretreatment. Lowered HS-CRP by 0.528 mg/l (P < 0.05) and decreased a DNA damage biomarker. Increased HDL-C marginally (WMD: 1.473 mg/dl, p = 0.012). Reduced Diastolic BP by 2.77 mmHg (95 %CI: −4.34, −1.19). Significantly reduced blood malondialdehyde and IL-6 in T2DM patients. Significantly restored skin moisture content (p = 0.03), improved elasticity (p = 0.009) but marginally decreased wrinkle depth (p = 0.11) compared to placebo. Impact of astaxanthin supplementation on blood pressure: A systematic review and meta-analysis of randomized controlled trials, 2021 This systematic review and meta-analysis on...